A biotech company offering a range of drug discovery services, Aakha Biologics is structured around development of novel therapeutic antibodies targeting MHC Class I Chain-Related Protein A (MICA). With the focus and emphasis on innovative approaches in oncology, these antibodies are designed to enhance immune clearance by reducing tumor cell evasion, contributing to cancer treatment strategies. One arena of emphasis is Bispecific Immune Cell Engager - a novel first-in-class biospecific immune cell engager aimed at addressing the hostile tumor micro-environment of advanced non-small cell lung cancer.
